Telomere length and polygenic risk scores (PRS) are linked to idiopathic pulmonary fibrosis (IPF) risk, especially in noncarriers of rare genetic variants. The study identified rare damaging variants ...

Over a century after Mendel established the foundations of inheritance, genomics has revealed that most human traits and common diseases arise from the ...

Please provide your email address to receive an email when new articles are posted on . Researchers said common risk variants help explain why epilepsy occurs in some family members and not others.

Using twin data from TEDS, researchers compared polygenic score prediction within families and across the population. They found that about half of predictive power for cognitive and educational ...

Polygenic risk scores (PRS) combined with clinical factors improve POAG risk prediction, aiding in identifying high-risk patients. The study used OHTS data, showing low polygenic risk correlates with ...

Incorporating a polygenic risk score into prostate cancer screening could enhance the detection of clinically significant prostate cancer that conventional screening may miss, according to results of ...

The optimism is not unfounded. In specific, well-defined clinical scenarios, polygenic scores are beginning to demonstrate some tangible utility. For cardiovascular disease, MI-GENES, a 10-year follow ...

Please provide your email address to receive an email when new articles are posted on . Polygenic score was a stronger predictor of TSH levels than free T 4 in two study cohorts. Using polygenic score ...

Cost-utility studies provide critical information for the costs and benefits of using any new test, typically building on existing public health and screening programmes, within a defined population.

Combining a polygenic risk score (PRS) with traditional biomarkers can help clinicians better estimate a patient’s risk of developing coronary artery disease (CAD), according to new UK Biobank data.

Evaluating RSPO2 activation and its association with outcomes and potential role as a driver in double-negative prostate cancer (DNPC). This is an ASCO Meeting Abstract from the 2025 ASCO ...